2001
DOI: 10.1159/000049789
|View full text |Cite
|
Sign up to set email alerts
|

Nuclear Medicine Techniques for the Diagnosis and Therapy of Prostate Carcinoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
11
0

Year Published

2007
2007
2017
2017

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 19 publications
(11 citation statements)
references
References 39 publications
0
11
0
Order By: Relevance
“…59,60 Taking advantage of both favorable characteristics of 18 F-Fluoride and the better performance of PET scanners, 18 F-Fluoride has been found to be more sensitive for detection of bone metastases than 99m Tc-MDP bone scanning. 61–64 Even-Sapir and colleagues showed that 18 F-Fluoride PET/CT is more sensitive and specific for detecting bone metastases in patients with high risk prostate cancer. 65 Unfortunately, follow up duration for patients with negative 18 F-Fluoride PET/CT scans was only 6 months, which may not have been sufficient to truly rule out false negative cases.…”
Section: Positron Emission Tomographymentioning
confidence: 99%
“…59,60 Taking advantage of both favorable characteristics of 18 F-Fluoride and the better performance of PET scanners, 18 F-Fluoride has been found to be more sensitive for detection of bone metastases than 99m Tc-MDP bone scanning. 61–64 Even-Sapir and colleagues showed that 18 F-Fluoride PET/CT is more sensitive and specific for detecting bone metastases in patients with high risk prostate cancer. 65 Unfortunately, follow up duration for patients with negative 18 F-Fluoride PET/CT scans was only 6 months, which may not have been sufficient to truly rule out false negative cases.…”
Section: Positron Emission Tomographymentioning
confidence: 99%
“…Pal et al (2008) suggest that bone scan is omitted in asymptomatic men who have a PSA < 20 ng/mL; however, in practice as bone scans are usually readily available and are cheap to perform the threshold is usually lower (Oyen et al , 2001) but is not required if the PSA is < 10 (Cook and Fogelman, 2001). They are usually undertaken with a Gleason score of ≥ 3 + 4 = 7, when there is bone pain (Buscombe, 2008) and when there is raised ALP regardless of the PSA level (Heidenreich et al , 2009).…”
Section: Metastatic Bone Diseasementioning
confidence: 99%
“…In addition, whenever PSA levels increase it is critical to accurately pinpoint the location of cancer recurrence or metastatic spread. Visualization of prostate cancer with PET using [ 18 F]FDG as a radiopharmaceutical is limited by the low uptake of FDG in the primary tumor, and to a lesser extent by high bladder activities [252,253]. It is well documented that more effective PET radiopharmaceuticals are required for this indication, and several laboratories are working to develop improved agents [55,[254][255][256][257][258][259][260][261][262][263][264][265][266][267][268].…”
Section: G Sigma Receptors In Oncologymentioning
confidence: 99%